{
  "metadata": {
    "graph_path": "./logic_graph.png",
    "num_solutions": 3,
    "family_stats": {
      "1": {
        "core": 1,
        "branch": 0
      },
      "2": {
        "core": 1,
        "branch": 1
      }
    }
  },
  "knowledge_base": {
    "rules": [
      {
        "id": "Rule1",
        "formal": "(A1 → A3)",
        "prover9_expression": "(published(research_team, clinical_trial) -> peer_reviewed(journal, study))",
        "natural": "Whenever the research team published the clinical trial, the journal peer-reviewed the study."
      },
      {
        "id": "Rule2",
        "formal": "(A11 → A10)",
        "prover9_expression": "(investigated(ethics_board, misconduct) -> retracted(journal, paper))",
        "natural": "Under the condition that the ethics board investigated misconduct, the journal retracted the paper."
      },
      {
        "id": "Rule3",
        "formal": "(A14 → (A12 → (A5 → G)))",
        "prover9_expression": "(certified(irb, protocol) -> (valid(protocol) -> (manufactured(company, drug_x) -> available(market, drug_x))))",
        "natural": "In the event the IRB certified the protocol, then if the protocol is valid, manufacturing drug X by the company leads to drug X being available on the market."
      },
      {
        "id": "Rule4",
        "formal": "(A6 → A8)",
        "prover9_expression": "(funded(nih, research) -> completed(research_team, phase_3_trial))",
        "natural": "Provided the NIH funded the research, the research team completed the phase 3 trial."
      },
      {
        "id": "Rule5",
        "formal": "(A6 ∨ A7)",
        "prover9_expression": "(funded(nih, research) | funded(pharma_company, research))",
        "natural": "Either the NIH funded the research, or the pharma company funded the research."
      },
      {
        "id": "Rule6",
        "formal": "(A7 → (A5 → G))",
        "prover9_expression": "(funded(pharma_company, research) -> (manufactured(company, drug_x) -> available(market, drug_x)))",
        "natural": "Under the condition that the pharma company funded the research, then manufacturing drug X by the company results in drug X being available on the market."
      },
      {
        "id": "Rule7",
        "formal": "(¬(A13 → A14) → A15)",
        "prover9_expression": "(-(compliant(team, regulations) -> certified(irb, protocol)) -> penalized(fda, company))",
        "natural": "If it is not the case that team compliance with regulations leads to IRB certification of the protocol, then the FDA penalized the company."
      },
      {
        "id": "Rule8",
        "formal": "(¬(A13 → A14) → ¬A15)",
        "prover9_expression": "(-(compliant(team, regulations) -> certified(irb, protocol)) -> -penalized(fda, company))",
        "natural": "Should it not hold that team compliance with regulations implies IRB certification of the protocol, then the FDA did not penalize the company."
      },
      {
        "id": "Rule9",
        "formal": "(¬(A3 → A2) → A4)",
        "prover9_expression": "(-(peer_reviewed(journal, study) -> approved(fda, drug_x)) -> rejected(fda, drug_x))",
        "natural": "Provided that peer review by the journal does not imply FDA approval of drug X, then the FDA rejected drug X."
      },
      {
        "id": "Rule10",
        "formal": "(¬(A8 → (A5 → G)) → ¬A9)",
        "prover9_expression": "(-(completed(research_team, phase_3_trial) -> (manufactured(company, drug_x) -> available(market, drug_x))) -> -suspended(fda, trial))",
        "natural": "If it is not the case that completing the phase 3 trial by the research team implies drug X availability upon manufacturing, then the FDA did not suspend the trial."
      },
      {
        "id": "Rule11",
        "formal": "(¬(¬(A8 → (A5 → G)) → A9) → A11)",
        "prover9_expression": "(-(-(completed(research_team, phase_3_trial) -> (manufactured(company, drug_x) -> available(market, drug_x))) -> suspended(fda, trial)) -> investigated(ethics_board, misconduct))",
        "natural": "Provided that the negation of phase 3 trial completion implying drug X availability does not result in FDA trial suspension, then the ethics board investigated misconduct."
      },
      {
        "id": "Rule12",
        "formal": "(¬G → A1)",
        "prover9_expression": "(-available(market, drug_x) -> published(research_team, clinical_trial))",
        "natural": "If drug X is not available on the market, then the research team published the clinical trial."
      }
    ],
    "facts": [
      {
        "id": "Fact1",
        "formal": "A12",
        "prover9_expression": "valid(protocol)",
        "natural": "The protocol is valid."
      },
      {
        "id": "Fact2",
        "formal": "A13",
        "prover9_expression": "compliant(team, regulations)",
        "natural": "The team is compliant with regulations."
      },
      {
        "id": "Fact3",
        "formal": "A5",
        "prover9_expression": "manufactured(company, drug_x)",
        "natural": "The company manufactured drug X."
      },
      {
        "id": "Fact4",
        "formal": "¬A10",
        "prover9_expression": "-retracted(journal, paper)",
        "natural": "The journal did not retract the paper."
      },
      {
        "id": "Fact5",
        "formal": "¬A2",
        "prover9_expression": "-approved(fda, drug_x)",
        "natural": "The FDA did not approve drug X."
      },
      {
        "id": "Fact6",
        "formal": "¬A4",
        "prover9_expression": "-rejected(fda, drug_x)",
        "natural": "The FDA did not reject drug X."
      }
    ]
  },
  "target": {
    "formal": "G",
    "prover9": "G",
    "prover9_expression": "available(market, drug_x)",
    "natural": "Drug X is available on the market."
  },
  "solutions": [
    {
      "id": 1,
      "family_id": 1,
      "path_type": "core",
      "branch_from": null,
      "steps": [
        {
          "step_number": 1,
          "rule_applied": "MT",
          "premises_used": [
            "(-(A3 -> A2) -> A4)",
            "-A4"
          ],
          "conclusion": "(A3 -> A2)",
          "natural": "If the journal peer-reviewed the study, then the FDA approved drug X."
        },
        {
          "step_number": 2,
          "rule_applied": "HS",
          "premises_used": [
            "(A1 -> A3)",
            "(A3 -> A2)"
          ],
          "conclusion": "(A1 -> A2)",
          "natural": "Provided the research team published the clinical trial, the FDA approved drug X."
        },
        {
          "step_number": 3,
          "rule_applied": "MT",
          "premises_used": [
            "(A1 -> A2)",
            "-A2"
          ],
          "conclusion": "-A1",
          "natural": "It is not the case that the research team published the clinical trial."
        },
        {
          "step_number": 4,
          "rule_applied": "MT",
          "premises_used": [
            "(-G -> A1)",
            "-A1"
          ],
          "conclusion": "G",
          "natural": "Drug X is available on the market."
        }
      ]
    },
    {
      "id": 2,
      "family_id": 2,
      "path_type": "core",
      "branch_from": null,
      "steps": [
        {
          "step_number": 1,
          "rule_applied": "HS",
          "premises_used": [
            "(-(-(A8 -> (A5 -> G)) -> A9) -> A11)",
            "(A11 -> A10)"
          ],
          "conclusion": "(-(-(A8 -> (A5 -> G)) -> A9) -> A10)",
          "natural": "Should it not hold that the negation of phase 3 trial completion leading to drug X availability implies FDA trial suspension, then the journal retracted the paper."
        },
        {
          "step_number": 2,
          "rule_applied": "MT",
          "premises_used": [
            "(-(-(A8 -> (A5 -> G)) -> A9) -> A10)",
            "-A10"
          ],
          "conclusion": "(-(A8 -> (A5 -> G)) -> A9)",
          "natural": "In the event that completion of the phase 3 trial by the research team does not lead to drug X being available on the market if the company manufactured it, then the FDA suspended the trial."
        },
        {
          "step_number": 3,
          "rule_applied": "RAA",
          "premises_used": [
            "(-(A8 -> (A5 -> G)) -> A9)",
            "(-(A8 -> (A5 -> G)) -> -A9)"
          ],
          "conclusion": "(A8 -> (A5 -> G))",
          "natural": "If the research team completed the phase 3 trial, then the company manufacturing drug X implies drug X is available on the market."
        },
        {
          "step_number": 4,
          "rule_applied": "HS",
          "premises_used": [
            "(A6 -> A8)",
            "(A8 -> (A5 -> G))"
          ],
          "conclusion": "(A6 -> (A5 -> G))",
          "natural": "Assuming the NIH funded the research, then if the company manufactured drug X, drug X becomes available on the market."
        },
        {
          "step_number": 5,
          "rule_applied": "DE",
          "premises_used": [
            "(A6 | A7)",
            "(A6 -> (A5 -> G))",
            "(A7 -> (A5 -> G))"
          ],
          "conclusion": "(A5 -> G)",
          "natural": "Should the company manufacture drug X, then drug X is available on the market."
        },
        {
          "step_number": 6,
          "rule_applied": "MP",
          "premises_used": [
            "(A5 -> G)",
            "A5"
          ],
          "conclusion": "G",
          "natural": "Drug X is available on the market."
        }
      ]
    },
    {
      "id": 3,
      "family_id": 2,
      "path_type": "branch",
      "branch_from": 4,
      "steps": [
        {
          "step_number": 1,
          "rule_applied": "RAA",
          "premises_used": [
            "(-(A13 -> A14) -> A15)",
            "(-(A13 -> A14) -> -A15)"
          ],
          "conclusion": "(A13 -> A14)",
          "natural": "Provided the team is compliant with regulations, the IRB certified the protocol."
        },
        {
          "step_number": 2,
          "rule_applied": "HS",
          "premises_used": [
            "(A13 -> A14)",
            "(A14 -> (A12 -> (A5 -> G)))"
          ],
          "conclusion": "(A13 -> (A12 -> (A5 -> G)))",
          "natural": "Given that the team is compliant with regulations, then if the protocol is valid, the company manufacturing drug X implies drug X is available on the market."
        },
        {
          "step_number": 3,
          "rule_applied": "MP",
          "premises_used": [
            "(A13 -> (A12 -> (A5 -> G)))",
            "A13"
          ],
          "conclusion": "(A12 -> (A5 -> G))",
          "natural": "If the protocol is valid, then whenever the company manufactured drug X, drug X becomes available on the market."
        },
        {
          "step_number": 4,
          "rule_applied": "MP",
          "premises_used": [
            "(A12 -> (A5 -> G))",
            "A12"
          ],
          "conclusion": "(A5 -> G)",
          "natural": "Should the company manufacture drug X, then drug X is available on the market."
        },
        {
          "step_number": 5,
          "rule_applied": "MP",
          "premises_used": [
            "(A5 -> G)",
            "A5"
          ],
          "conclusion": "G",
          "natural": "Drug X is available on the market."
        }
      ]
    }
  ],
  "translations": {
    "domain_theme": "Pharmaceutical Research",
    "atomic_facts": {
      "A1": "published(research_team, clinical_trial)",
      "A2": "approved(fda, drug_x)",
      "A3": "peer_reviewed(journal, study)",
      "A4": "rejected(fda, drug_x)",
      "A5": "manufactured(company, drug_x)",
      "A6": "funded(nih, research)",
      "A7": "funded(pharma_company, research)",
      "A8": "completed(research_team, phase_3_trial)",
      "A9": "suspended(fda, trial)",
      "A10": "retracted(journal, paper)",
      "A11": "investigated(ethics_board, misconduct)",
      "A12": "valid(protocol)",
      "A13": "compliant(team, regulations)",
      "A14": "certified(irb, protocol)",
      "A15": "penalized(fda, company)",
      "G": "available(market, drug_x)"
    },
    "natural_facts": {
      "A1": "The research team published the clinical trial.",
      "A2": "The FDA approved drug X.",
      "A3": "The journal peer-reviewed the study.",
      "A4": "The FDA rejected drug X.",
      "A5": "The company manufactured drug X.",
      "A6": "The NIH funded the research.",
      "A7": "The pharma company funded the research.",
      "A8": "The research team completed the phase 3 trial.",
      "A9": "The FDA suspended the trial.",
      "A10": "The journal retracted the paper.",
      "A11": "The ethics board investigated misconduct.",
      "A12": "The protocol is valid.",
      "A13": "The team is compliant with regulations.",
      "A14": "The IRB certified the protocol.",
      "A15": "The FDA penalized the company.",
      "G": "Drug X is available on the market."
    },
    "prover9_expressions": [
      "(published(research_team, clinical_trial) -> approved(fda, drug_x))",
      "(published(research_team, clinical_trial) -> peer_reviewed(journal, study))",
      "(investigated(ethics_board, misconduct) -> retracted(journal, paper))",
      "(valid(protocol) -> (manufactured(company, drug_x) -> available(market, drug_x)))",
      "(compliant(team, regulations) -> (valid(protocol) -> (manufactured(company, drug_x) -> available(market, drug_x))))",
      "(compliant(team, regulations) -> certified(irb, protocol))",
      "(certified(irb, protocol) -> (valid(protocol) -> (manufactured(company, drug_x) -> available(market, drug_x))))",
      "(peer_reviewed(journal, study) -> approved(fda, drug_x))",
      "(manufactured(company, drug_x) -> available(market, drug_x))",
      "(funded(nih, research) -> (manufactured(company, drug_x) -> available(market, drug_x)))",
      "(funded(nih, research) -> completed(research_team, phase_3_trial))",
      "(funded(nih, research) | funded(pharma_company, research))",
      "(funded(pharma_company, research) -> (manufactured(company, drug_x) -> available(market, drug_x)))",
      "(completed(research_team, phase_3_trial) -> (manufactured(company, drug_x) -> available(market, drug_x)))",
      "(-(compliant(team, regulations) -> certified(irb, protocol)) -> penalized(fda, company))",
      "(-(compliant(team, regulations) -> certified(irb, protocol)) -> -penalized(fda, company))",
      "(-(peer_reviewed(journal, study) -> approved(fda, drug_x)) -> rejected(fda, drug_x))",
      "(-(completed(research_team, phase_3_trial) -> (manufactured(company, drug_x) -> available(market, drug_x))) -> suspended(fda, trial))",
      "(-(completed(research_team, phase_3_trial) -> (manufactured(company, drug_x) -> available(market, drug_x))) -> -suspended(fda, trial))",
      "(-(-(completed(research_team, phase_3_trial) -> (manufactured(company, drug_x) -> available(market, drug_x))) -> suspended(fda, trial)) -> retracted(journal, paper))",
      "(-(-(completed(research_team, phase_3_trial) -> (manufactured(company, drug_x) -> available(market, drug_x))) -> suspended(fda, trial)) -> investigated(ethics_board, misconduct))",
      "(-available(market, drug_x) -> published(research_team, clinical_trial))",
      "valid(protocol)",
      "compliant(team, regulations)",
      "manufactured(company, drug_x)",
      "available(market, drug_x)",
      "-published(research_team, clinical_trial)",
      "-retracted(journal, paper)",
      "-approved(fda, drug_x)",
      "-rejected(fda, drug_x)"
    ],
    "natural_expressions": [
      "Provided the research team published the clinical trial, the FDA approved drug X.",
      "Whenever the research team published the clinical trial, the journal peer-reviewed the study.",
      "Under the condition that the ethics board investigated misconduct, the journal retracted the paper.",
      "If the protocol is valid, then whenever the company manufactured drug X, drug X becomes available on the market.",
      "Given that the team is compliant with regulations, then if the protocol is valid, the company manufacturing drug X implies drug X is available on the market.",
      "Provided the team is compliant with regulations, the IRB certified the protocol.",
      "In the event the IRB certified the protocol, then if the protocol is valid, manufacturing drug X by the company leads to drug X being available on the market.",
      "If the journal peer-reviewed the study, then the FDA approved drug X.",
      "Should the company manufacture drug X, then drug X is available on the market.",
      "Assuming the NIH funded the research, then if the company manufactured drug X, drug X becomes available on the market.",
      "Provided the NIH funded the research, the research team completed the phase 3 trial.",
      "Either the NIH funded the research, or the pharma company funded the research.",
      "Under the condition that the pharma company funded the research, then manufacturing drug X by the company results in drug X being available on the market.",
      "If the research team completed the phase 3 trial, then the company manufacturing drug X implies drug X is available on the market.",
      "If it is not the case that team compliance with regulations leads to IRB certification of the protocol, then the FDA penalized the company.",
      "Should it not hold that team compliance with regulations implies IRB certification of the protocol, then the FDA did not penalize the company.",
      "Provided that peer review by the journal does not imply FDA approval of drug X, then the FDA rejected drug X.",
      "In the event that completion of the phase 3 trial by the research team does not lead to drug X being available on the market if the company manufactured it, then the FDA suspended the trial.",
      "If it is not the case that completing the phase 3 trial by the research team implies drug X availability upon manufacturing, then the FDA did not suspend the trial.",
      "Should it not hold that the negation of phase 3 trial completion leading to drug X availability implies FDA trial suspension, then the journal retracted the paper.",
      "Provided that the negation of phase 3 trial completion implying drug X availability does not result in FDA trial suspension, then the ethics board investigated misconduct.",
      "If drug X is not available on the market, then the research team published the clinical trial.",
      "The protocol is valid.",
      "The team is compliant with regulations.",
      "The company manufactured drug X.",
      "Drug X is available on the market.",
      "It is not the case that the research team published the clinical trial.",
      "The journal did not retract the paper.",
      "The FDA did not approve drug X.",
      "The FDA did not reject drug X."
    ],
    "node_mappings": {
      "(A1 → A2)": {
        "formal": "(A1 → A2)",
        "prover9": "(A1 -> A2)",
        "prover9_expression": "(published(research_team, clinical_trial) -> approved(fda, drug_x))",
        "natural": "Provided the research team published the clinical trial, the FDA approved drug X."
      },
      "(A1 → A3)": {
        "formal": "(A1 → A3)",
        "prover9": "(A1 -> A3)",
        "prover9_expression": "(published(research_team, clinical_trial) -> peer_reviewed(journal, study))",
        "natural": "Whenever the research team published the clinical trial, the journal peer-reviewed the study."
      },
      "(A11 → A10)": {
        "formal": "(A11 → A10)",
        "prover9": "(A11 -> A10)",
        "prover9_expression": "(investigated(ethics_board, misconduct) -> retracted(journal, paper))",
        "natural": "Under the condition that the ethics board investigated misconduct, the journal retracted the paper."
      },
      "(A12 → (A5 → G))": {
        "formal": "(A12 → (A5 → G))",
        "prover9": "(A12 -> (A5 -> G))",
        "prover9_expression": "(valid(protocol) -> (manufactured(company, drug_x) -> available(market, drug_x)))",
        "natural": "If the protocol is valid, then whenever the company manufactured drug X, drug X becomes available on the market."
      },
      "(A13 → (A12 → (A5 → G)))": {
        "formal": "(A13 → (A12 → (A5 → G)))",
        "prover9": "(A13 -> (A12 -> (A5 -> G)))",
        "prover9_expression": "(compliant(team, regulations) -> (valid(protocol) -> (manufactured(company, drug_x) -> available(market, drug_x))))",
        "natural": "Given that the team is compliant with regulations, then if the protocol is valid, the company manufacturing drug X implies drug X is available on the market."
      },
      "(A13 → A14)": {
        "formal": "(A13 → A14)",
        "prover9": "(A13 -> A14)",
        "prover9_expression": "(compliant(team, regulations) -> certified(irb, protocol))",
        "natural": "Provided the team is compliant with regulations, the IRB certified the protocol."
      },
      "(A14 → (A12 → (A5 → G)))": {
        "formal": "(A14 → (A12 → (A5 → G)))",
        "prover9": "(A14 -> (A12 -> (A5 -> G)))",
        "prover9_expression": "(certified(irb, protocol) -> (valid(protocol) -> (manufactured(company, drug_x) -> available(market, drug_x))))",
        "natural": "In the event the IRB certified the protocol, then if the protocol is valid, manufacturing drug X by the company leads to drug X being available on the market."
      },
      "(A3 → A2)": {
        "formal": "(A3 → A2)",
        "prover9": "(A3 -> A2)",
        "prover9_expression": "(peer_reviewed(journal, study) -> approved(fda, drug_x))",
        "natural": "If the journal peer-reviewed the study, then the FDA approved drug X."
      },
      "(A5 → G)": {
        "formal": "(A5 → G)",
        "prover9": "(A5 -> G)",
        "prover9_expression": "(manufactured(company, drug_x) -> available(market, drug_x))",
        "natural": "Should the company manufacture drug X, then drug X is available on the market."
      },
      "(A6 → (A5 → G))": {
        "formal": "(A6 → (A5 → G))",
        "prover9": "(A6 -> (A5 -> G))",
        "prover9_expression": "(funded(nih, research) -> (manufactured(company, drug_x) -> available(market, drug_x)))",
        "natural": "Assuming the NIH funded the research, then if the company manufactured drug X, drug X becomes available on the market."
      },
      "(A6 → A8)": {
        "formal": "(A6 → A8)",
        "prover9": "(A6 -> A8)",
        "prover9_expression": "(funded(nih, research) -> completed(research_team, phase_3_trial))",
        "natural": "Provided the NIH funded the research, the research team completed the phase 3 trial."
      },
      "(A6 ∨ A7)": {
        "formal": "(A6 ∨ A7)",
        "prover9": "(A6 | A7)",
        "prover9_expression": "(funded(nih, research) | funded(pharma_company, research))",
        "natural": "Either the NIH funded the research, or the pharma company funded the research."
      },
      "(A7 → (A5 → G))": {
        "formal": "(A7 → (A5 → G))",
        "prover9": "(A7 -> (A5 -> G))",
        "prover9_expression": "(funded(pharma_company, research) -> (manufactured(company, drug_x) -> available(market, drug_x)))",
        "natural": "Under the condition that the pharma company funded the research, then manufacturing drug X by the company results in drug X being available on the market."
      },
      "(A8 → (A5 → G))": {
        "formal": "(A8 → (A5 → G))",
        "prover9": "(A8 -> (A5 -> G))",
        "prover9_expression": "(completed(research_team, phase_3_trial) -> (manufactured(company, drug_x) -> available(market, drug_x)))",
        "natural": "If the research team completed the phase 3 trial, then the company manufacturing drug X implies drug X is available on the market."
      },
      "(¬(A13 → A14) → A15)": {
        "formal": "(¬(A13 → A14) → A15)",
        "prover9": "(-(A13 -> A14) -> A15)",
        "prover9_expression": "(-(compliant(team, regulations) -> certified(irb, protocol)) -> penalized(fda, company))",
        "natural": "If it is not the case that team compliance with regulations leads to IRB certification of the protocol, then the FDA penalized the company."
      },
      "(¬(A13 → A14) → ¬A15)": {
        "formal": "(¬(A13 → A14) → ¬A15)",
        "prover9": "(-(A13 -> A14) -> -A15)",
        "prover9_expression": "(-(compliant(team, regulations) -> certified(irb, protocol)) -> -penalized(fda, company))",
        "natural": "Should it not hold that team compliance with regulations implies IRB certification of the protocol, then the FDA did not penalize the company."
      },
      "(¬(A3 → A2) → A4)": {
        "formal": "(¬(A3 → A2) → A4)",
        "prover9": "(-(A3 -> A2) -> A4)",
        "prover9_expression": "(-(peer_reviewed(journal, study) -> approved(fda, drug_x)) -> rejected(fda, drug_x))",
        "natural": "Provided that peer review by the journal does not imply FDA approval of drug X, then the FDA rejected drug X."
      },
      "(¬(A8 → (A5 → G)) → A9)": {
        "formal": "(¬(A8 → (A5 → G)) → A9)",
        "prover9": "(-(A8 -> (A5 -> G)) -> A9)",
        "prover9_expression": "(-(completed(research_team, phase_3_trial) -> (manufactured(company, drug_x) -> available(market, drug_x))) -> suspended(fda, trial))",
        "natural": "In the event that completion of the phase 3 trial by the research team does not lead to drug X being available on the market if the company manufactured it, then the FDA suspended the trial."
      },
      "(¬(A8 → (A5 → G)) → ¬A9)": {
        "formal": "(¬(A8 → (A5 → G)) → ¬A9)",
        "prover9": "(-(A8 -> (A5 -> G)) -> -A9)",
        "prover9_expression": "(-(completed(research_team, phase_3_trial) -> (manufactured(company, drug_x) -> available(market, drug_x))) -> -suspended(fda, trial))",
        "natural": "If it is not the case that completing the phase 3 trial by the research team implies drug X availability upon manufacturing, then the FDA did not suspend the trial."
      },
      "(¬(¬(A8 → (A5 → G)) → A9) → A10)": {
        "formal": "(¬(¬(A8 → (A5 → G)) → A9) → A10)",
        "prover9": "(-(-(A8 -> (A5 -> G)) -> A9) -> A10)",
        "prover9_expression": "(-(-(completed(research_team, phase_3_trial) -> (manufactured(company, drug_x) -> available(market, drug_x))) -> suspended(fda, trial)) -> retracted(journal, paper))",
        "natural": "Should it not hold that the negation of phase 3 trial completion leading to drug X availability implies FDA trial suspension, then the journal retracted the paper."
      },
      "(¬(¬(A8 → (A5 → G)) → A9) → A11)": {
        "formal": "(¬(¬(A8 → (A5 → G)) → A9) → A11)",
        "prover9": "(-(-(A8 -> (A5 -> G)) -> A9) -> A11)",
        "prover9_expression": "(-(-(completed(research_team, phase_3_trial) -> (manufactured(company, drug_x) -> available(market, drug_x))) -> suspended(fda, trial)) -> investigated(ethics_board, misconduct))",
        "natural": "Provided that the negation of phase 3 trial completion implying drug X availability does not result in FDA trial suspension, then the ethics board investigated misconduct."
      },
      "(¬G → A1)": {
        "formal": "(¬G → A1)",
        "prover9": "(-G -> A1)",
        "prover9_expression": "(-available(market, drug_x) -> published(research_team, clinical_trial))",
        "natural": "If drug X is not available on the market, then the research team published the clinical trial."
      },
      "A12": {
        "formal": "A12",
        "prover9": "A12",
        "prover9_expression": "valid(protocol)",
        "natural": "The protocol is valid."
      },
      "A13": {
        "formal": "A13",
        "prover9": "A13",
        "prover9_expression": "compliant(team, regulations)",
        "natural": "The team is compliant with regulations."
      },
      "A5": {
        "formal": "A5",
        "prover9": "A5",
        "prover9_expression": "manufactured(company, drug_x)",
        "natural": "The company manufactured drug X."
      },
      "G": {
        "formal": "G",
        "prover9": "G",
        "prover9_expression": "available(market, drug_x)",
        "natural": "Drug X is available on the market."
      },
      "¬A1": {
        "formal": "¬A1",
        "prover9": "-A1",
        "prover9_expression": "-published(research_team, clinical_trial)",
        "natural": "It is not the case that the research team published the clinical trial."
      },
      "¬A10": {
        "formal": "¬A10",
        "prover9": "-A10",
        "prover9_expression": "-retracted(journal, paper)",
        "natural": "The journal did not retract the paper."
      },
      "¬A2": {
        "formal": "¬A2",
        "prover9": "-A2",
        "prover9_expression": "-approved(fda, drug_x)",
        "natural": "The FDA did not approve drug X."
      },
      "¬A4": {
        "formal": "¬A4",
        "prover9": "-A4",
        "prover9_expression": "-rejected(fda, drug_x)",
        "natural": "The FDA did not reject drug X."
      }
    }
  }
}